Most short peptides are flexible, and flexibility costs you twice: the peptide pays an entropic penalty every time it binds, and proteases find an extended chain easy to cut. Constraining a peptide addresses both. This hub compares the main ways to do it, what each one costs to make, and how to decide which fits your sequence.
A flexible peptide in solution samples a very large number of conformations, and only a small fraction of them resemble the shape that binds a target. Locking the chain into, or close to, the binding conformation reduces the entropy lost on binding, which can improve affinity without changing a single side chain. The same rigidity tends to improve protease resistance, because most proteases need to thread an extended stretch of backbone through their active site, and a constrained ring does not present one.
Neither benefit is guaranteed. A constraint applied in the wrong place can lock the peptide into a shape that does not bind at all, which is why constrained analogues are normally made as a small set rather than one compound. The background on why short peptides are flexible in the first place is on our peptide folding page.
| Strategy | What is joined | Best for | Watch out for |
|---|---|---|---|
| Disulfide | Two cysteine side chains | Reproducing a native disulfide; a quick, reversible loop | Reducible inside cells; with more than one pair, the pairing must be directed |
| Head-to-tail (backbone) | N-terminus to C-terminus | Strong protease resistance; no free termini at all | Cyclization yield falls for very short sequences; can be slow and low-yielding |
| Side-chain to side-chain | Commonly a lysine amine to an aspartate or glutamate acid, forming a lactam | Constraining part of a sequence while leaving the termini free | Consumes two side chains, which must not be ones the target needs |
| Staple | A hydrocarbon bridge between two non-natural residues | Stabilizing an α-helix | Requires special amino acids and extra chemistry; placement must follow the helical turn |
With one pair of cysteines, oxidation gives one product and the chemistry is routine. With two or three pairs, random oxidation gives a mixture of isomers with the same mass, which mass spectrometry cannot tell apart. The way round this is orthogonal cysteine protection: each pair carries a different protecting group, removed in sequence so that one disulfide is formed and closed before the next is unmasked. That is a design decision, not a detail, and it has to be specified when you order.
Tell us the pairing, not just the positions
A sequence with four cysteines has three possible pairing patterns. If you only give the positions, any of the three could be what arrives. State which cysteine pairs with which, and we will choose the protection scheme that delivers it. For dissolving and handling the result, see dissolving peptides with disulfide bonds.
A flexible peptide loses entropy when it binds, and an extended backbone is easy for proteases to cut. Locking the chain near its binding conformation can improve affinity without changing any side chain, and usually improves protease resistance at the same time.
A disulfide joins two cysteine side chains and can be reduced, including inside cells. A head-to-tail cyclic peptide joins the N-terminus to the C-terminus through the backbone, leaves no free termini, and is not reversible.
By orthogonal cysteine protection: each pair carries a different protecting group, removed in sequence so one disulfide is formed and closed before the next is unmasked. Specify which cysteine pairs with which when ordering, since a four-cysteine sequence has three possible patterns.
No. Disulfide isomers have identical masses. Confirming connectivity requires a digest or a dedicated experiment.
Not reliably. Some macrocycles cross membranes well and many do not. Rigidity alone does not confer permeability, and cell entry is a separate design question.
Research use only. LifeTein peptides and proteins are supplied for laboratory research use. They are not for human or veterinary use, and not for diagnostic or therapeutic use. See our research use policy.